BTIG raises Adeptus Biotechnologies price target to $34 on guidelines
BTIG raised its price target for Adeptus Biotechnologies (ADPT) to $34 from $25, citing updated cancer guidelines that feature its clonoSEQ assay. The stock has gained 109% over the past year. Adaptive Biotechnologies reported Q2 revenue of $71.6M, up 22% YoY, but missed earnings estimates. Guggenheim and BTIG also raised their price targets for Adaptive Biotechnologies.
How this was made
The 30-second read
Why it matters
The upgrade could attract short‑term buying, but investors should monitor payer adoption and competitive landscape.
Market read
Analyst action on a niche biotech with a clear regulatory catalyst; relevant for traders focused on biotech upgrades.
What to watch
Potential competition from emerging MRD assays and regulatory timing uncertainties.
Background
BTIG upgraded ADPT after NCCN guidelines highlighted its assay, while also noting analyst consensus on strong volume growth.
Ticker impact
BTIG raised ADPT price target to $34, citing new NCCN guidelines that name its clonoSEQ assay, suggesting higher future test utilization.
Potential upside of 5‑10% over the next few weeks if market digests the guidance lift.
Target increase is based on concrete regulatory guideline inclusion, a material catalyst for volume growth.
Market effects
Boosts sentiment for the broader minimal residual disease testing sector and AI‑driven diagnostics.
Limited to U.S. biotech investors; no broader regional effect.
Minor, confined to niche oncology diagnostics market.
Counterpoint
The price target raise may be premature if payer reimbursement does not follow guideline adoption.
Key entities
- Analyst FirmBTIG
Raised price target for ADPT to $34.
- Guideline BodyNational Comprehensive Cancer Network (NCCN)
Issued updated multiple myeloma guidelines mentioning ADPT's assay.
